Overview

Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This randomized phase I trial is studying the side effects and best dose of Se-methyl-seleno-L-cysteine in healthy adult men. Studying samples of blood, urine, and toenail clippings in the laboratory from healthy men receiving Se-methyl-seleno-L-cysteine may help doctors learn more about how Se-methyl-seleno-L-cysteine works in the body.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Selenomethylselenocysteine